Uncovering the Potential: Terns Pharmaceuticals Receives Price Target Increase from Oppenheimer – Here’s Why
The Future of Terns Pharmaceuticals: A Promising Outlook An Exciting Update from Oppenheimer Recently, Oppenheimer raised the price target on Terns Pharmaceuticals to $20 from $17 and maintained an Outperform rating on the shares. This news has created quite a buzz in the pharmaceutical industry, with investors eagerly anticipating the potential growth of the company….